Covaxin

The World Health Organisation is expected to review and take a final call on an emergency use listing for Covaxin shots on October 26. The organisation is reviewing the data to decide whether the approval will be given for which several Indians are waiting to travel abroad. If all goes well, the positive decision of the WHO will help Indians who've received the vaccine.  

Bharat Biotech after submitting vaccine trial reports of "Covaxin" amongst beneficiaries aged between 2-8 years, said that they are awaiting the approval from the drug regulators. Upon receiving approval, Covaxin will become "one of the first vaccines in the world" to be administered to beneficiaries belonging to the said age group. After reviewing the results, the Subject Expert Committee (SEC) recommended the grant of the vaccine.

The World Health Organization (WHO) has not yet granted Covaxin emergency use Authorization. It is India's domestically produced coronavirus vaccine. On October 5, the Strategic Advisory Group of Experts on Immunization (SAGE) will have a meeting to discuss the Emergency Use Listing (EUL) for Covaxin. The four-day meeting of the expert group to deliberate on policy recommendations began on October 4. Only six vaccine candidates have been… read-more

As per reports, India's drug regulator has allowed Covishield's maker Serum Institute of India (SII) to enroll children aged between seven to 11 years for its COVID-19 vaccine trial. The Central Drugs Standard Control Organisation's (CDSCO) subject expert panel made the recommendation after "detailed deliberation". SII is already conducting a trial of its COVID-19 vaccine in the 12-17 age group and has presented safety data for an initial 100… read-more

India will now receive vaccines in the market as Health Minister Mansukh Mandaviya has released the first commercial batch of COVID-19 vaccine "Covaxin" developed by Bharat Biotech in its new plant, based in Gujarat's Ankleshwar on August 29. Reportedly, the Hyderabad-based firm in may announced to open the plant to produce 200 million doses of vaccine. Mandaviya also said that it will strengthen the country's fight against coronavirus.